Phase IV studies are planned in countries that may be among the first to introduce the RTS,S/AS01E (MosquirixTM) malaria vaccine. The development of specific communications strategies that include the identification of information, education, and communication materials will therefore initially focus on these countries currently planned to participate in Phase IV activities.

A generic communication strategy was developed by PATH Malaria Vaccine Initiative (MVI) in collaboration with GlaxoSmithKline (GSK) to support these countries in the development of their country-specific communications strategies.

In this context, AMP supported the work of dedicated national communication committees, mostly composed of staff from national programs for vaccination and malaria control, in developing national communications strategies in preparation for possible implementation of the RTS,S/AS01E malaria candidate vaccine following regulatory approval and national recommendation.